Early Access — free while we kick the tires
EdgarHawk

TRV GP V, LLC

10% Owner

10% Owner

Latest: Insider selling · April 2026

3 filings analyzed · 1 company · Latest 2026-05-13

Never miss a filing from TRV GP V, LLC

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Rapport Therapeutics, Inc. RAPP 0 3 Net selling

Activity

May 2026
2026-05-13 Rapport Therapeutics, Inc. RAPP 10b5-1 Plan Joint filing
low
Sell
133,618 shares
$5,377,323
Significance 3/10

10% owner Third Rock Ventures V sells 133,618 shares for $5.4M; 4th sale at RAPP in 36 months with consistent prior exits well-timed as stock fell after each.

Third Rock Ventures V, a significant 10% beneficial owner, is shedding shares for the fourth time in the past three years—a pattern of repeated exits rather than accumulation. This latest sale occurred at a modest premium to the stock's recent trading range, and the fund's prior three exits at RAPP all proved well-timed, with the stock declining following each one, suggesting disciplined capital allocation. Rapport itself remains unprofitable with mounting quarterly losses, and while the stock has rallied notably in recent months, it still trades below its 52-week high. The fund's consistent exits here—now representing a reduction of over 2% of Third Rock Ventures V's original stake—underscore an institutional perspective: rebalancing a holding in a loss-making biotech rather than conviction-level accumulation typical of insider buyers betting on turnaround momentum.

2026-05-11 Rapport Therapeutics, Inc. RAPP 10b5-1 Plan Joint filing
low
Sell
276,513 shares
$11,094,906
Significance 3/10

Third Rock Ventures V (10% owner) sells 276k shares for $11.1M; first exit since well-timed prior sale, but stock up significantly in recent months.

L.P. Third Rock Ventures V, a significant institutional holder with over 10% ownership, divested a modest 4.1% of its stake across two sales in early May. The fund's prior sale at this company was well-timed—shares declined afterward—setting a positive precedent for exit decisions. However, this current sale arrives after the stock has gained substantially over recent months and still trades below its 52-week high, an environment where exits traditionally signal less urgency. The company remains unprofitable with mounting losses, though it generated meaningful quarterly revenue, creating a mixed fundamental backdrop. For a portfolio manager of this scale, modest portfolio rebalancing is routine, though the timing—after significant recent gains—suggests a pragmatic trim rather than alarm about deteriorating fundamentals or imminent business deterioration.

April 2026
2026-04-21 Rapport Therapeutics, Inc. RAPP 10b5-1 Plan Joint filing
low
Sell
426,005 shares
$17,175,244
Significance 3/10

Third Rock Ventures V sold 426,005 shares of RAPP at $40.32 on 2026-04-17 under 10b5-1 plan; holds 6.71M shares post-sale

Third Rock Ventures V, a 10% owner, executed a scheduled sale of 426,005 shares for $17,175,243.59 under a pre-arranged 10b5-1 trading plan. The transaction reduced the fund's holding from 7,135,233 shares to 6,709,228 shares, a 6.0% reduction. Because this sale follows a pre-arranged trading plan rather than a discretionary decision, it does not signal a change in conviction or strategic reassessment by the insider; it reflects a predetermined execution schedule. The fund retains substantial ownership, maintaining a 10% stake post-transaction.